Oral GLP-1 recommendation, thyroid eye disease treatment and maternal-health supplies.
EMA’s medicines committee recommended authorisation of Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. The recommendation now awaits a European Commission decision before EU marketing authorisation.
Why it matters: Could broaden oral treatment options and influence competition, access planning and patient choice in metabolic care.
Read at EMA →Roche announced US approval of satralizumab for adults with thyroid eye disease, allowing subcutaneous administration at home after training. SatraGO-2 demonstrated improvements in eye bulging and double vision, although the companion SatraGO-1 trial missed its prespecified primary endpoint.
Why it matters: Adds a treatment option with a different administration model, potentially reducing infusion-related logistical burdens for patients and services.
Read at Roche →UNICEF confirmed a one-year, $25 million US-funded agreement to procure and deliver maternal, child-health and selected nutrition supplies to at least 15 countries. The arrangement follows prolonged supply disruption; UNICEF said new orders were expected shortly but had not yet been placed.
Why it matters: Supports continuity of essential medicines and equipment while highlighting continuing procurement and delivery risks in vulnerable health systems.
Read at Reuters →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.